SCHEMBL6947802

SCHEMBL6947802

CCCN1CCC(=O)CC1.CCCNCCC

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
ALDH1A1 P00352 3/20 0.36
THRB P10828 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 1/20 0.36
DRD2 P14416 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
MEN1 O00255 1/20 0.33
RECQL P46063 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6947485 0.89 POLB (0.38) POLBALDH1A1THRBL3MBTL1NPC1
SCHEMBL6948499 0.89 ALDH1A1 (0.39) ALDH1A1THRBL3MBTL1DRD2SIGMAR1
SCHEMBL8114400 0.88 POLB (0.46) POLBALDH1A1THRBL3MBTL1NPC1
SCHEMBL1180845 0.88 POLB (0.46) POLBALDH1A1THRBL3MBTL1NPC1
SCHEMBL6942247 0.87 GNAI3 (0.41)
Diethylamine SCHEMBL6947450 0.86 POLB (0.41) POLBALDH1A1THRBL3MBTL1NPC1
SCHEMBL6949948 0.86 KDM4E (0.37) ALDH1A1L3MBTL1CYP2D6KMT2A
SCHEMBL8115348 0.86 KDM4E (0.37) ALDH1A1L3MBTL1CYP2D6KMT2A
Dimethylamine SCHEMBL6946290 0.86 POLB (0.42) POLBALDH1A1THRBL3MBTL1NPC1
Bromide SCHEMBL3742304 0.86 POLB (0.45) POLBALDH1A1THRBL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 POLB 413/4885ALDH1A1 2147/4885THRB 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.